Special Report: Dimerix has received the initial payment of ¥300 million (A$3.2 million) in line with its recently announced ...

Dimerix Ltd (ASX:DXB) has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries ...

Some healthcare analysts believe Neuren Pharmaceuticals (ASX:NEU) shares should be worth more than double their current soft ...

In a report released on February 21, Tanushree Jain from Petra Capital maintained a Buy rating on Dimerix Limited (DXB – Research Report), with ...

Investor reaction to PolyNovo's (ASX:PNV) half-year numbers shows how even seemingly minor earnings misses can result in a ...

Dr Nina Webster is the CEO and managing director of Dimerix (ASX:DXB), which in mid-CY25 is due to report the second interim results of its ACTION3 global phase III trial of lead drug DMX-200 to treat ...

The Middle East healthcare sector is undergoing rapid expansion presenting opportunities for ASX-listed companies.

Highlights:,Financial Performance:,Dimerix recorded a widened net loss, reflecting an increase compared to the previous reporting period.,Share Movement:,The company's stock experienced a decline over ...

Healthcare analysts say Neuren shares should be worth more than double what they are Biotech sector retreats in February, despite some record results Dimerix pockets $3.2 million payment from Japanese ...

Dimerix pursues new product concepts and applies scientific knowledge to the discovery of products from early stage development through to commercialisation.